Shares of Sarepta Therapeutics Inc. surged 4.9% in premarket trade Monday, after the biopharmaceutical company said it planned to submit a New Drug Application (NDA) for its Duchenne muscular dystrophy treatment. The company said that based on favorable phase 1/2 study results and feedback from the Food and Drug Administration for golodirsen, the company intends to complete a rolling submission of an NDA by the end of 2018. The stock has run up 40% over the past three months, while the iShares Nasdaq Biotechnology ETF has climbed 8.1% and the S&P 500 has gained 4.6%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News